VIEW试验事后分析:nAMD延长给药间隔的结局与疾病特征
该事后分析评估VIEW试验第2年接受阿柏西普或雷珠单抗每12周或更长间隔(≥q12周)或短于12周间隔(<q12周)注射的nAMD眼。第96周时,基线隐匿型CNV及第52周视网膜积液和渗漏与<q12周给药相关;无论给药间隔,第52周视力获益在第96周维持。
要点
- 基线非隐匿型CNV及第52周无视网膜积液和渗漏与≥q12周给药显著相关。
- 第2年接受≥q12周或<q12周给药的眼,第52周视力获益均维持至第96周。
- 研究为VIEW试验事后分析,结果需谨慎解读。
核心结论
- 基线CNV类型非隐匿型及第52周无视网膜积液和渗漏与≥q12周给药间隔显著相关。
- 接受≥q12周和<q12周给药的眼在第96周均维持第52周视力改善。
研究设计与样本
- VIEW试验的事后分析,纳入随机临床试验数据。
- 第1年眼接受雷珠单抗每4周(Rq4)、阿柏西普2 mg每4周(2q4)或阿柏西普2 mg每8周(2q8,初始3次每月注射)。
- 第2年眼接受pro re nata治疗,至少每12周强制治疗一次。
主要发现
- 第96周,Rq4、2q4和2q8组分别有218眼(42.5%)、284眼(53.9%)和245眼(47.9%)在第2年接受≥q12周间隔治疗。
- Rq4、2q4和2q8组分别有295眼(57.5%)、243眼(46.1%)和266眼(52.1%)接受<q12周间隔治疗。
- 基线隐匿型CNV(P = .0156)、第52周视网膜积液(P < .0001)和渗漏(P < .0001)与<q12周给药相关。
- ≥q12周给药组Rq4、2q4和2q8的BCVA增益:第52周分别为8.7、9.9和9.7字母,第96周分别为8.5、8.8和9.2字母。
- <q12周给药组相应增益:第52周分别为10.3、9.7和8.9字母,第96周分别为9.1、7.7和8.1字母。
关键数值与推荐
- 基线非隐匿型CNV和第52周无视网膜积液和渗漏与≥q12周给药间隔显著相关。
- 第2年治疗间隔≥q12周或<q12周的眼均维持第52周视力获益至第96周。
临床怎么用
- 基线CNV类型非隐匿型且第52周无视网膜积液和渗漏的眼,可考虑≥q12周延长给药间隔。
- 延长给药间隔至≥q12周时,第52周视力获益可维持至第96周。
局限性
- 为VIEW试验的事后分析,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate outcomes and disease characteristics in eyes with neovascular age-related macular degeneration that received intravitreal aflibercept injection (IAI) and ranibizumab every 12 weeks or longer (≥q12 weeks) or less than every 12 weeks (<q12 weeks) during year 2 of VIEW studies. DESIGN: Post hoc analysis of randomized clinical trial data. METHODS: In year 1, eyes received ranibizumab q4 weeks (Rq4), IAI 2 mg q4 weeks (2q4), or IAI 2 mg q8 weeks after 3 monthly injections (2q8). In year 2, eyes received pro re nata treatment, with mandatory treatment at least q12 weeks. RESULTS: At week 96, 218 (42.5%), 284 (53.9%), and 245 (47.9%) eyes treated with Rq4, 2q4, and 2q8, respectively, received treatment at ≥q12-week intervals and 295 (57.5%), 243 (46.1%), and 266 (52.1%) eyes at <12q-week intervals during the second year. Baseline occult-type choroidal neovascularization (CNV) (P = .0156) and retinal fluid (P < .0001) and leakage (P < .0001) at week 52 were associated with <q12-week dosing. Mean best-corrected visual acuity gains from baseline with Rq4, 2q4, and 2q8 at ≥q12-week interval were 8.7, 9.9, and 9.7 letters at week 52 and 8.5, 8.8, and 9.2 letters at week 96, respectively. The corresponding gains with <q12-week dosing were 10.3, 9.7, and 8.9 letters at week 52 and 9.1, 7.7, and 8.1 letters at week 96. CONCLUSIONS: Baseline CNV type other than occult and absence of retinal fluid and leakage at week 52 were significantly associated with ≥q12-week dosing. Vision improvements at week 52 following a year of fixed dosing with ranibizumab and IAI were maintained at week 96 in eyes that received treatment ≥q12 weeks and <q12 weeks.
引用
- Khurana RN, Rahimy E, Joseph WA, et al. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials. Am J Ophthalmol. 2019. PMID: 30664844. doi:10.1016/j.ajo.2019.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。